Hemolytic uremic syndrome (HUS) is a disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia—a reduced platelet count—and acute injury to the kidneys. It belongs to the group of disorders called thrombotic microangiopathies, in which injury to small blood vessels promotes microscopic clot formation and organ damage. Most childhood cases follow infection with Shiga toxin–producing Escherichia coli, but HUS also occurs through uncontrolled complement activation and other mechanisms. Although kidney injury is its defining organ manifestation, severe disease can affect the nervous system, heart, and gastrointestinal tract.
Mechanism
The central abnormality is damage to the endothelium, the cell layer lining blood vessels, particularly within the kidney’s small vessels and filtering structures. Endothelial injury promotes platelet activation and small-vessel thrombosis. Platelets are consumed in these lesions, while red blood cells become fragmented as they pass through damaged vessels.
This mechanical destruction of red cells, termed microangiopathic hemolysis, produces characteristic fragments called schistocytes on a blood film. Reduced blood flow and endothelial dysfunction impair kidney filtration, causing acute kidney injury. The three components of the syndrome may develop at different times, so the full triad is not always present at the first assessment.
The term “uremic” reflects the accumulation of waste products when kidney function declines; it does not mean that every affected person initially has the full clinical syndrome of uremia.
Causes and classification
Shiga toxin–associated HUS
Shiga toxin–producing E. coli–associated HUS, usually abbreviated STEC-HUS, is the most common form in children. It typically follows an intestinal infection with abdominal pain and diarrhea, which is frequently bloody. HUS usually develops several days after the gastrointestinal illness begins, sometimes as the diarrhea is improving.
Shiga toxin damages susceptible cells by interfering with protein synthesis. Its interaction with receptors on vascular cells contributes to endothelial injury, especially in the kidneys. E. coli O157:H7 is a well-known cause, but numerous non-O157 strains can also cause HUS. Shiga toxin–producing Shigella dysenteriae type 1 is another recognized cause.
STEC infection can be transmitted through contaminated food or water, contact with infected animals, and person-to-person spread. Not every STEC infection progresses to HUS.
Complement-mediated HUS
Complement-mediated HUS results from inadequate regulation of the complement system, a network of proteins involved in immune defense. Excessive complement activity injures vascular endothelium and promotes thrombotic microangiopathy.
Underlying abnormalities may include pathogenic variants affecting complement regulation or acquired antibodies against complement factor H. A detectable genetic abnormality is not found in every case. Genetic susceptibility also does not inevitably cause disease: infection, pregnancy, or another physiological stress may precipitate an episode.
This form has traditionally been called “atypical HUS” or aHUS. However, atypical HUS has historically also served as a broader label for HUS not associated with Shiga toxin. Consequently, it is not a completely precise synonym for a proven complement-mediated disorder.
Other HUS and overlapping disorders
HUS can occur with invasive pneumococcal infection. Pneumococcal enzymes alter cell-surface carbohydrates, contributing to red cell destruction and vascular injury.
Thrombotic microangiopathy may also occur in association with certain medicines, severe hypertension, autoimmune diseases, malignancy, and transplantation. These conditions are often classified as secondary thrombotic microangiopathies rather than grouped indiscriminately under HUS. Their mechanisms can overlap with complement-mediated disease.
The older division into “diarrhea-positive” and “diarrhea-negative” HUS is imperfect: diarrhea can accompany complement-mediated disease, and a preceding diarrheal illness may be absent or unrecognized in STEC-HUS.
Clinical features
Kidney manifestations include reduced urine production, blood or protein in the urine, fluid retention, and elevated blood pressure. Severe cases may cause little or no urine output. Anemia can produce pallor, weakness, and fatigue, while low platelet counts may be associated with bruising or pinpoint skin hemorrhages.
Neurological involvement may include irritability, confusion, seizures, or impaired consciousness. Gastrointestinal complications can include severe colitis, and other organs may also be affected. Clinical severity ranges from disease that resolves with supportive treatment to multiorgan illness requiring intensive care.
Diagnosis and distinction from related conditions
Diagnosis combines clinical findings with laboratory evidence of hemolysis, reduced platelets, and kidney injury. Investigations commonly include:
- A complete blood count and blood film.
- Tests showing red cell destruction, such as elevated lactate dehydrogenase and reduced haptoglobin.
- Blood creatinine, electrolytes, and urine examination.
- Stool testing for Shiga toxin or its genes and testing for STEC.
- Tests directed at alternative causes of thrombotic microangiopathy.
A central differential diagnosis is thrombotic thrombocytopenic purpura (TTP), usually associated with severe deficiency of the enzyme ADAMTS13. Kidney injury tends to be more prominent in HUS, but clinical features overlap and cannot reliably distinguish the disorders by themselves. ADAMTS13 testing therefore has an important role in assessment.
Other alternatives include disseminated intravascular coagulation, severe hypertension-associated microangiopathy, and pregnancy-associated disorders.
Complement protein measurements, testing for factor H antibodies, and genetic investigations can help characterize suspected complement-mediated disease. Normal circulating complement concentrations do not exclude it, and genetic results alone do not establish the cause of an acute episode. Kidney biopsy is not routinely necessary in a classic presentation; when performed, it can demonstrate thrombotic microangiopathy but does not necessarily identify its cause.
Treatment
Treatment depends on the mechanism and severity of disease.
STEC-associated disease
Management is primarily supportive and generally takes place in hospital. It includes careful management of fluid balance, electrolytes, blood pressure, and complications. Red blood cell transfusion may be necessary for significant anemia. Dialysis temporarily replaces some kidney functions when kidney injury causes severe metabolic disturbances or fluid overload.
Antibiotics are not routine treatment for STEC infection or established STEC-HUS. Some antibiotics may increase the risk of HUS during STEC infection; their effects vary by agent and clinical context. Antibiotics remain important for distinct infections, including pneumococcal-associated disease.
Plasma exchange and complement inhibitors are not established routine treatments for uncomplicated STEC-HUS.
Complement-mediated disease
Complement inhibitors, including eculizumab and ravulizumab, block complement protein C5 and are used for complement-mediated HUS. These monoclonal antibodies can control ongoing microangiopathy and improve kidney outcomes, although recovery depends partly on the extent of existing injury.
Terminal complement inhibition increases susceptibility to meningococcal infection. Its use therefore involves specific vaccination and infection-prevention measures. Plasma exchange has a role in selected circumstances, particularly when TTP remains a diagnostic possibility or in some antibody-mediated presentations.
Course and long-term outcomes
Many children with STEC-HUS recover kidney function, including some who require dialysis during the acute illness. Nevertheless, persistent protein in the urine, hypertension, or chronic kidney disease can develop after apparent recovery. Severe neurological complications and irreversible kidney failure occur in a minority of cases.
Complement-mediated HUS may relapse. Recurrence risk varies with the underlying abnormality and treatment history, and recurrence can also affect a transplanted kidney. Long-term assessment commonly considers kidney function, urinary protein, and blood pressure rather than relying solely on resolution of anemia and thrombocytopenia.